The stock of ValiRx Plc (LON:VAL) is a huge mover today! The stock decreased 3.40% or GBX 0.22 on November 30, hitting GBX 6.4. About 560,331 shares traded hands. ValiRx Plc (LON:VAL) has declined 33.75% since May 2, 2016 and is downtrending. It has underperformed by 38.98% the S&P500.
The move comes after 9 months positive chart setup for the GBX 5.43M company. It was reported on Nov, 30 by Barchart.com. We have GBX 6.91 PT which if reached, will make LON:VAL worth GBX 434,400 more.
ValiRx Plc (LON:VAL) Ratings Coverage
Out of 2 analysts covering ValiRx PLC (LON:VAL), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. ValiRx PLC has been the topic of 25 analyst reports since September 16, 2015 according to StockzIntelligence Inc. Beaufort Securities maintained the stock with “Speculative Buy” rating in Friday, July 8 report. On Tuesday, November 29 the stock rating was maintained by Northland Capital with “Corporate”. The stock of ValiRx Plc (LON:VAL) has “Corporate” rating given on Wednesday, September 16 by Northland Capital. As per Thursday, November 5, the company rating was maintained by Northland Capital. Beaufort Securities maintained the shares of VAL in a report on Friday, July 29 with “Speculative Buy” rating. Beaufort Securities maintained ValiRx Plc (LON:VAL) on Thursday, August 11 with “Speculative Buy” rating. The stock of ValiRx Plc (LON:VAL) earned “Speculative Buy” rating by Beaufort Securities on Tuesday, June 7. The stock has “Speculative Buy” rating given by Beaufort Securities on Wednesday, November 30. The firm has “Corporate” rating given on Thursday, July 7 by Northland Capital. As per Thursday, October 13, the company rating was maintained by Northland Capital.
Another recent and important ValiRx Plc (LON:VAL) news was published by Uk.Finance.Yahoo.com which published an article titled: “-LSE Ticker: WWYSP4/ISIN: GB00BWWYSP41” on March 17, 2014.
ValiRx plc is a biopharmaceutical company. The company has a market cap of 5.43 million GBP. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It currently has negative earnings. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.